325457-62-3

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[4-amino-2-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester
• CAS NO: 325457-62-3
• Molecular Formula: C17H23F3N2O3
• Molecular Weight: 360.376
• Mol File: 325457-62-3.mol

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[4-amino-2-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[4-amino-2-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester(325457-62-3)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[4-amino-2-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester(325457-62-3)

Safety Data

• Hazardous Substances Data: 325457-62-3(Hazardous Substances Data)

Usage

Purpose

Building block for the synthesis of various chemical compounds in the pharmaceutical industry

Physical form

White to off-white powder

Solubility

Sparingly soluble in water

Use

Preparation of pharmaceutical drugs

Potential applications

Medicinal chemistry due to its ability to bind to specific receptors in the body and modulate biological processes

Safety precautions

Handle with care and follow proper safety protocols to prevent adverse effects on human health and the environment.

Upstream product

• 1535-76-8 4-amino-2-(trifluoromethyl)phenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 325457-61-2 4-(N-(t-butoxycarbonyl)piperidin-4-yl)oxy-3-trifluoromethyl-1-nitrobenzene 
• 141-78-6 ethyl acetate 
• 400-74-8 2-Fluoro-5-nitrobenzotrifluoride 

Downstream Products

• 337519-90-1 ethyl N-[4-(1-t-butoxycarbonylpiperidin-4-yloxy)-3-trifluoromethylphenyl]sulfamoylacetate 

Relevant articles and documents

PROTEIN KINASE C INHIBITORS AND USES THEREOF

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to ph

Cinnamyl derivatives: Synthesis and factor Xa (FXa) inhibitory activities

To develop a potent and oral anticoagulant, a series of compounds with cinnamyl moiety was synthesized and their factor Xa (FXa) inhibitory activities were examined. As a result, some cinnamyl derivatives showed potent FXa inhibitory activities in vitro. Among them, compounds with substituent at the 3-position on the central benzene ring represented by (N-{4-[1-(acetimidoyl) piperidin-4-yloxy]-3-chlorophenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl] sulfamoyl)acetic acid dihydrochloride (45b) and (N-{4-[1-(acetimidoyl)piperidin- 4-yloxy]-3-carbamoylphenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl]sulfamoyl) acetic acid dihydrochloride (45j) exhibited potent FXa inhibitory activities with IC50 values of less than 10 nM in vitro. These compounds also showed potent anticoagulant activities both in vitro and ex vivo. Furthermore, these compounds exhibited no lethal toxicity (30 mg/kg, i.v.).

BISARYLUREA DERIVATIVES

The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

BENZAMIDINE DERIVATIVE

Compounds of general formula (1) and pharmacologically acceptable salts thereof: ???[wherein ??????R1 represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; ??????R2 represents a hydrogen atom or a halogen atom; ??????R3 represents a hydrogen atom, an alkyl group which may be substituted, an aralkyl group, an alkylcarbonyl group which may be substituted, an alkylsulfonyl group which may be substituted or the like; ??????each of R4 and R5 represents a hydrogen atom, a halogen atom, an alkyl group which may be substituted, a carbamoyl group or the like; ??????R6 represents a heterocycle or the like; ??????each of R7 and R8 represents a hydrogen atom, an alkyl group or the like; ??????n represents 0, 1 or 2] ???exhibit excellent activated blood coagulation factor X inhibitory activity and are useful for the prevention or treatment of blood coagulation-related diseases.

BENZAMIDINE DERIVATIVES

Benzamidine derivatives of formula (I) or pharmaceutically acceptable salts thereof exhibit excellent inhibitory activity against factor Xa and are useful for treating or preventing blood coagulation disorders: wherein R 1represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; R 2represents a hydrogen atom, a halogen atom or an alkyl group, R 3represents a hydrogen atom, an optionally substituted alkyl group, an aralkyl group, an optionally substituted alkanoyl group or an optionally substituted alkylsulfonyl group, R 4and R 5 are the same as or different from each other and each represent a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an alkoxy group, a carboxyl group, an alkoxycarbonyl group or an optionally substituted carbamoyl group, and R 6represents a substituted pyrrolidine group or substituted piperidine group.

Design and synthesis of aminophenol-based factor Xa inhibitors

A novel potent and selective aminophenol scaffold for fXa inhibitors was developed from a previously reported benzimidazole-based naphthylamidine template. The aminophenol template is more synthetically accessible than the benzimidazole template, which si

Benzenamine derivatives as anti-coagulants

This invention is directed to benzenamine derivatives of formula (I): wherein A, W, m, n, R1, R2, R3, R4, R5and R6are defined herein. These compounds are useful as anti-coagulants.